These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11915937)

  • 1. Factor Xa--a promising target for drug development.
    Kaiser B
    Cell Mol Life Sci; 2002 Feb; 59(2):189-92. PubMed ID: 11915937
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
    Becker RC; Alexander J; Dyke CK; Harrington RA
    Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of novel oral anticoagulants.
    Abo-Salem E; Becker RC
    Curr Opin Pharmacol; 2016 Apr; 27():86-91. PubMed ID: 26939028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DaXa-inhibition assay: A concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs.
    van Pelt LJ; Lukens MV; Testa S; Chatelain B; Douxfils J; Mullier F
    Thromb Res; 2018 Aug; 168():63-66. PubMed ID: 29909093
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic direct and indirect factor Xa inhibitors.
    Samama MM
    Thromb Res; 2002 May; 106(3):V267-73. PubMed ID: 12356488
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct Factor Xa and direct thrombin inhibitors: a clinical trial update.
    Turpie AG
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):497-508. PubMed ID: 19562646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
    Perzborn E; Roehrig S; Straub A; Kubitza D; Misselwitz F
    Nat Rev Drug Discov; 2011 Jan; 10(1):61-75. PubMed ID: 21164526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on factor Xa inhibition.
    Rai R; Sprengeler PA; Elrod KC; Young WB
    Curr Med Chem; 2001 Feb; 8(2):101-19. PubMed ID: 11172669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective factor Xa inhibition for thromboprophylaxis.
    Eikelboom JW; Weitz JI
    Lancet; 2008 Jul; 372(9632):6-8. PubMed ID: 18582929
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel anticoagulants based on direct inhibition of thrombin and factor Xa.
    Gardell SJ; Sanderson PE
    Coron Artery Dis; 1998; 9(2-3):75-81. PubMed ID: 9647407
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel direct factor IIa and Xa inhibitors: mechanisms of action and preclinical studies.
    Deftereos S; Anatoliotakis N; Giannopoulos G; Kaoukis A; Mavri M; Pyrgakis V; Stefanadis C
    Curr Clin Pharmacol; 2012 Aug; 7(3):149-65. PubMed ID: 22564123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis.
    Dang YP; Chen YF; Li YQ; Zhao L
    Mini Rev Med Chem; 2017; 17(4):338-350. PubMed ID: 27292781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
    Danalev D
    Mini Rev Med Chem; 2012 Jul; 12(8):721-30. PubMed ID: 22512557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Throwing it in reverse: An update on reversal of oral factor Xa inhibitors.
    Gilbert BW; Reeder JA; Alkhalifah MA; Moran DA; Corvino MA
    Am J Emerg Med; 2019 Oct; 37(10):1978-1980. PubMed ID: 30987915
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity.
    Masters JJ; Franciskovich JB; Tinsley JM; Campbell C; Campbell JB; Craft TJ; Froelich LL; Gifford-Moore DS; Hay LA; Herron DK; Klimkowski VJ; Kurz KD; Metz JT; Ratz AM; Shuman RT; Smith GF; Smith T; Towner RD; Wiley MR; Wilson A; Yee YK
    J Med Chem; 2000 Jun; 43(11):2087-92. PubMed ID: 10841787
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New reversal agent for factor Xa inhibitors shows promise.
    Ghadimi K; Welsby IJ
    Evid Based Med; 2016 Jun; 21(3):96. PubMed ID: 26951451
    [No Abstract]   [Full Text] [Related]  

  • 20. Factor Xa inhibitors: next-generation antithrombotic agents.
    Pinto DJ; Smallheer JM; Cheney DL; Knabb RM; Wexler RR
    J Med Chem; 2010 Sep; 53(17):6243-74. PubMed ID: 20503967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.